Allergy Therapeutics (AGY) has provided a trading update for the six months to December 2024, noting that the financial turnaround of the business continues to progress as 1H25 marks the second consecutive half-year period of expected revenue growth. Revenue in 1H FY25 is expected to be £34.0m (1H24: £33.6m) representing 1% growth on a reported basis, or more than 4% on a constant currency basis. Additionally, the volume of units sold increased by 5% indicating a recovery in manufactory output, ....
